PTC Therapeutics Crecimiento futuro

Future controles de criterios 0/6

PTC Therapeutics se prevé un crecimiento anual de los beneficios y los ingresos de 44.3% y 0.06%, respectivamente, mientras que el BPA aumentará de grow a 45.7%.

Información clave

44.3%

Tasa de crecimiento de los beneficios

45.7%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	20.7%
Tasa de crecimiento de los ingresos	0.06%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	11 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Mar 03

PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options

Feb 11

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Jun 23

Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price

May 18

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Mar 02

PTC pauses enrollment in mid-stage study for Huntington's disease candidate in U.S.

Oct 19

PTC Therapeutics betas topline expectations, strengthens commercial portfolio

Aug 05

PTC Therapeutics gene therapy Upstaza wins approval in EU for ultra-rare neuromuscular disorder

Jul 20

PTC Therapeutics: DMD Trial News Unlikely To Restore Flagging Share Price

Jun 24

Are PTC Therapeutics, Inc. (NASDAQ:PTCT) Investors Paying Above The Intrinsic Value?

May 27

PTC Therapeutics: One Of The Leaders In The Treatment Of Rare Diseases

Apr 11

Is Therapeutics (NASDAQ:PTCT) Using Debt Sensibly?

Feb 09

PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Could Be 35% Below Their Intrinsic Value Estimate

Dec 27

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:PTCT - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	750	-120	11	-17	8
12/31/2025	616	-355	-169	-183	12
12/31/2024	607	-457	-328	-216	13
12/31/2023	938	-627	-279	-158	N/A
9/30/2023	798	-642	-343	-224	N/A
6/30/2023	819	-618	-364	-248	N/A
3/31/2023	770	-571	-403	-289	N/A
12/31/2022	699	-559	-509	-357	N/A
9/30/2022	697	-531	-409	-260	N/A
6/30/2022	618	-556	-422	-273	N/A
3/31/2022	569	-522	-395	-249	N/A
12/31/2021	539	-524	-337	-251	N/A
9/30/2021	492	-455	-327	-247	N/A
6/30/2021	472	-391	-250	-169	N/A
3/31/2021	430	-454	-271	-213	N/A
12/31/2020	381	-438	-250	-194	N/A
9/30/2020	358	-441	-193	-140	N/A
6/30/2020	311	-432	-221	-182	N/A
3/31/2020	322	-292	-198	-138	N/A
12/31/2019	307	-252	-144	-99	N/A
9/30/2019	297	-222	-142	-104	N/A
6/30/2019	279	-213	-116	-85	N/A
3/31/2019	262	-181	-72	-54	N/A
12/31/2018	265	-128	-43	-28	N/A
9/30/2018	256	-78	0	9	N/A
6/30/2018	245	-61	-91	-10	N/A
3/31/2018	224	-69	-78	3	N/A
12/31/2017	194	-79	-90	-10	N/A
9/30/2017	142	-107	N/A	-45	N/A
6/30/2017	123	-108	N/A	-53	N/A
3/31/2017	90	-130	N/A	-91	N/A
12/31/2016	83	-142	N/A	-104	N/A
9/30/2016	70	-166	N/A	-121	N/A
6/30/2016	57	-174	N/A	-124	N/A
3/31/2016	48	-174	N/A	-129	N/A
12/31/2015	37	-170	N/A	-124	N/A
9/30/2015	37	-147	N/A	-102	N/A
6/30/2015	29	-131	N/A	-91	N/A
3/31/2015	24	-118	N/A	-80	N/A
12/31/2014	25	-94	N/A	-57	N/A
9/30/2014	17	-84	N/A	-64	N/A
6/30/2014	32	-62	N/A	-52	N/A
3/31/2014	37	-51	N/A	-53	N/A
12/31/2013	35	-66	N/A	-47	N/A
9/30/2013	37	-48	N/A	-43	N/A
6/30/2013	28	-51	N/A	-45	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: PTCT se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios frente mercado: PTCT se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: PTCT se prevé que siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: PTCT(0.06% al año) se prevé que crezca más despacio que el mercado de US (8.1% al año).

Ingresos de alto crecimiento: PTCTSe prevé que los ingresos de la empresa (0.06% al año) crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la Rentabilidad de los fondos propios de PTCT se prevé elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

PTC Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full-Year of 2024

Consensus EPS estimates fall by 10%

PTC Therapeutics, Inc. Updates Revenue Guidance for Full Year 2023

Price target decreased by 12% to US$45.64

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

Recent updates

PTC Therapeutics, Inc. to Report Q1, 2024 Results on Apr 25, 2024

PTC Therapeutics, Inc. Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA

ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency

PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Full year 2023 earnings: EPS misses analyst expectations

PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

PTC Therapeutics, Inc. to Report Q4, 2023 Results on Feb 29, 2024

PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options

CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarn (ataluren) Following Re-examination Procedure

Co-Founder notifies of intention to sell stock

CEO & Director recently sold US$274k worth of stock

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full-Year of 2024

CEO & Director notifies of intention to sell stock

PTC Therapeutics, Inc. Provides Updates on Translarna Regulatory Activities

Consensus EPS estimates fall by 10%

PTC Therapeutics, Inc. Updates Revenue Guidance for Full Year 2023

Third quarter 2023 earnings: EPS misses analyst expectations

PTC Therapeutics, Inc. to Report Q3, 2023 Results on Oct 26, 2023

New major risk - Financial position

Price target decreased by 12% to US$45.64

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

PTC Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

PTC Therapeutics, Inc. Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Ptc Therapeutics Shares Positive Interim Data from Pivot-Hd Clinical Trial in Huntington's Disease Patients

PTC Therapeutics, Inc. Announces Strategic Pipeline Prioritization

Consensus EPS estimates upgraded to US$4.26 loss

PTC Therapeutics, Inc. Announces Cessation of Emily Hill as Chief Financial Officer, Effective on August 20, 2023

Price target increased by 8.6% to US$57.64

PTC Therapeutics, Inc. Announces Aphenity Trial Achieves Primary Endpoint with Sepiapterin in Adult and Pediatric Patients with Phenylketonuria

Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CEO, COO & Director recently sold US$63k worth of stock

Executive VP & Chief Legal Officer notifies of intention to sell stock

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Forecast to breakeven in 2025

Co-Founder recently sold US$120k worth of stock

Chief Operating Officer notifies of intention to sell stock

Co-Founder recently sold US$86k worth of stock

PTC Therapeutics, Inc. Provides Revenue Guidance for the Year 2022 and 2023

PTC Therapeutics, Inc. Announces Resignation of Dawn Svoronos as Member of the Board of Directors

PTC Therapeutics, Inc. Announces That the Brazilian Health Regulatory Agency, Anvisa (Agência Nacional De Vigilância Sanitária), Has Approved Waylivra™ (Volanesorsen) as the First Treatment for Familial Partial Lipodystrophy (Fpl) in Brazil

Medicines and Healthcare Products Regulatory Agency Grants Marketing Authorization for PTC Therapeutics, Inc.'s Upstaza™

Price target decreased to US$51.46

Insufficient new directors

Price target decreased to US$52.31

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

PTC Therapeutics, Inc. announced that it expects to receive $499.999989 million in funding from Blackstone Alternative Credit Advisors LP, Blackstone Life Sciences Advisors L.L.C.

Executive VP & Chief Legal Officer exercised options and sold US$167k worth of stock

PTC Therapeutics, Inc. Provides Update on Ongoing Global PIVOT-HD Trial For PTC518

PTC pauses enrollment in mid-stage study for Huntington's disease candidate in U.S.

Executive VP & Chief Legal Officer notifies of intention to sell stock

Price target increased to US$54.64

Insider recently sold US$119k worth of stock

Consensus forecasts updated

PTC Therapeutics, Inc. Provides Key Clinical/Regulatory Updates

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

PTC Therapeutics betas topline expectations, strengthens commercial portfolio

PTC Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2022

PTC Therapeutics, Inc. Announces Upstaza™ Granted Marketing Authorization by European Commission as First Disease-Modifying Treatment for AADC Deficiency

PTC Therapeutics gene therapy Upstaza wins approval in EU for ultra-rare neuromuscular disorder

PTC Therapeutics: DMD Trial News Unlikely To Restore Flagging Share Price

PTC Therapeutics, Inc. Appoints Alethia Young to its Board of Directors

PTC Therapeutics, Inc. Announces Preliminary Results Presented At ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study

PTC Therapeutics, Inc. Announces FDA Approves Label Extension for Evrysdi for Infants with Spinal Muscular Atrophy Under 2 Months Old

Are PTC Therapeutics, Inc. (NASDAQ:PTCT) Investors Paying Above The Intrinsic Value?

PTC Therapeutics, Inc. Receives Positive CHMP Opinion for Upstaza™ for the Treatment of AADC Deficiency